ENA Respiratory appoints two strategic advisors to support leading project

Ella Day | May 7, 2025 | Appointment | Research and Development Ena Respiratory, Infections and infestations, Respirology, strategic adivsors 

ENA Respiratory, focused on minimising the impact of viral respiratory infections, has announced the appointment of Kenny Simmen (pictured left) and Alison Humbles (pictured right) as strategic advisors. In their roles, they will help move the company’s lead candidate, INNA-051, into a phase 2 trial.

Both Simmen and Humbles have rich experience in the infectious and respiratory diseases therapy area, with skills across R&D, business development and commercial strategy.

Humbles has held leading roles in projects across respiratory, autoimmunity, inflammatory and infectious disease. Most recently, she was disease area lead for respiratory at Roche. Prior, she held senior roles at MedImmune and worked as an academic at the Children’s Hospital, Harvard Medical School, Boston, US.

Advertisement

Currently, Simmen also holds positions as an independent advisor and board member for biotech companies worldwide. He worked at Johnson & Johnson for over 25 years, leading global external innovation and collaboration efforts through J&J Innovation.

ENA develops solutions that protect against common and emerging respiratory versus for which vaccines and direct-antivirals have limitations or do not exist. INNA-051 is the company’s lead asset, a nasal dry powder reducing the impact of viral respiratory infections in at-risk populations.

Christophe Demaison, CEO of ENA Respiratory, said: “Humbles and Simmens’ knowledge and experience will benefit ENA Respiratory as we continue to drive the clinical development of INNA-051 which we believe could offer a highly significant new approach to reducing the enormous burden of respiratory viral diseases.”

Ella Day
7/5/25

Related Content

nasal-spray-drawing

Novel prophylactic nasal spray reduced COVID-19 replication by 96% in animal studies

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost …

The Gateway to Local Adoption Series

Latest content